Skip navigation

Proactive Strategies to Manage Risk in Patient Support Services, Specialty Pharmacy Contracting and Non-Promotional Activities

September 14-15, 2017
  • Boston, MA

CBI’s 3rd annual Compliance Congress for Specialty Products is the life science industry’s only meeting catered to the unique compliance challenges for specialty pharmaceutical companies. Gain insights from key stakeholders through real-world case studies, vibrant panel discussions, and educational workshops on the future of specialty risk mitigation.

CLE Credits
Available! Pending Approval

While specialty products are immensely valuable to patients, they also bring unprecedented risks. A comprehensive compliance program is essential to correctly assessing HCP engagement, patient assistance, pharmacy distribution and more. This conference focuses on the highest priority risks that specialty compliance programs are tackling.

The ONLY Compliance Conference Designed for the Specialty Pharmaceutical and Biotech Industry

  • Gain insight into operational precautions for co-pay assistance and charitable donations
  • Input safeguards for securing patient data, deterring off-label recommendations and interacting with patients appropriately
  • Evaluate the pros and cons to running a pre-launch disease state awareness program
  • Help ensure independence and integrity of medical affairs and commercial functions
  • Explore specialty pharmacy contracting considerations —
    Core services vs. enhanced services
  • Balance effective patient assistance programs (PAPs) and maintaining compliant practices
  • Determine if a nurse educator field force is right for your organization and strategize around training a field force
    to fit your organizational needs
  • Developments in anti-corruption laws e.g., FCPA, Germany and the UK Bribery Act
  • Examine the most pressing compliance risks during R&D
    and clinical trials


MULTI-SESSION TOPIC INTENSIVE Mitigating Risks Associated with Patient and Advocacy Group Interactions
COMPLIANCE OFFICER FORUM Effective Governance with Limited Resources for Innovative Products
EXPERT PANEL A Spotlight on Medical Affairs and MSL Activities
LUNCH ‘N LEARN Emerging Compliance Priorities for 2018
FACILITATED DISCUSSION AND BENCHMARKING Noteworthy High Risk Zones for 2017 and Beyond — Examine Your Compliance Program


Paul Ham
Executive Director,
Corporate Compliance
(North America)

Masha Chestukhin
Associate Director,
Compliance Officer R&D, IA, FMV
Sanofi US

Alessandro Martuscelli
Chief Global
Therapeutics Counsel

Jerald Korn
Vice President,
Assistant General Counsel,
Chief Compliance Officer

Andrea Kocharyan
Vice President,
Legal Affairs
Boston BioMedical

Kyle Y. Faget
Senior Corporate Counsel
Jounce Therapeutics